This is a communication from the examiner in charge of your application.

**COMMISIONER OF PATENTS AND TRADEMARKS**

**JUN 10 1981**

- This application has been examined.
- Responsive to communication filed on:
- This action is made final.

A shortened statutory period for response to this action is set to expire **three** months, **—** days from the date of this letter. Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

**Part I  THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:**
- Notice of References Cited by Examiner, PTO-892
- Notice of Informal Patent Drawing, PTO-948
- Notice of References Cited by Applicant, PTO-1449
- Notice of Informal Patent Application, Form PTO-152

**Part II  SUMMARY OF ACTION**

1. **Claims 1-13** are pending in the application.

   Of the above, claims **—** are withdrawn from consideration.

2. **—** claims have been cancelled.

3. **—** claims are allowed.

4. **Claims 1, 2, 7-10** are rejected.

5. **Claims 3-6, 11-13** are objected to.

6. **—** claims are subject to restriction or election requirement.

7. **—** The formal drawings filed on **—** are acceptable.

8. **—** The drawing correction request filed on **—** has been **—** approved. **—** disapproved.

9. **—** Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has **—** been received. **—** not been received. **—** been filed in parent application, serial no. **—**.

10. **—** Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.

11. **—** Other
Claims 1, 2, 7-10 are rejected under 35 U.S.C. 103 as being obvious over Petrillo, Jr. (patent No. 4168267) in view of Ondetti et al. (patents 4105776, 4159355, 4234489), Krapcho (patent No. 4217359) British patents 2027025 and 2028327. Petrillo, Jr. discloses and claims phosphinylyl-alkanoyl substituted prolines of the following structures:

![Structure](image)

the only difference between the art compounds and the claimed ones is in the substituent on the proline moiety, various substituents for the claimed ones versus hydrogen for the art ones. However, the secondary references disclose the equivalencies among the following substituents: hydrogen, hydroxy, alkyl, halogen, carbamoxoyoxy, keto, phenyl, hydroxy-phenyl, cycloalkyl, ether, thioether and the like for structurally similar proline derivatives having antihypertensive activities. Accordingly, the claimed compounds are obvious over the art ones.

Claim 1 is rejected under 35 U.S.C. 112, paragraph 1. The specification does not contain a sufficient enabling disclosure with respect to the following terms - "alkyl",
Serial No. 212,911

Art Unit 121

"aryl", "arylalkyl", "cycloalkyl", "cycloalkylalkyl", "alkoxy" since there is no limit to the size and complexity of these groups claimed.

Claim 1 is rejected under 35 U.S.C. 112, paragraph 2. The claim is confusing since -OR₄ in the first structural formula is erroneous. The number 4' should be 4. Furthermore, cycloalkyl(alkyl) should be changed to cycloalkyalkyl.

Claims 3-6 and 11-13 are objected to as being dependent on a rejected claim.

Copies of prior art references have been considered and made of record. All have been used for the art rejection.

JTFan:elt

A/C 703
557-2517
05/27/81

Jane T. Fan